MHRA (Medicines and Healthcare products Regulatory Agency) issues POC (point of care) microalbuminuria test devices report:
This article was originally published in Clinica
Executive Summary
Point of care devices for the detection and semi-quantitation of microalbuminuria are the subject of the latest POC urine screening device evaluation report to be published by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The report includes technical and user assessments of analytical performance, suitability for point of care and reliability. The devices evaluated are: Bayer Microalbumin read of the Bayer Clinitek Status urine strip reader, Bayer Microalbustix, Roche Diagnostics' [Chemstrip] Micral test and Diagnostic Chemicals' ImmunoDip urinary albumin.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.